107. Juvenile idiopathic arthritis Clinical trials / Disease details
Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-001086-34-ES (EUCTR) | 21/10/2005 | 20/06/2005 | A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal study | A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal study | The present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 mpnths after documentation of remission on medication. | Trade Name: Metotrexato Product Name: Methotrexate Trade Name: Methotrexate Product Name: Methotrexate Product Code: L01BA01 | Istituto Giannina Gaslini-PRINTO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Denmark;Spain;Italy |